Log in using OpenID

Hereditary Angioedema Market To Grow Like Never Before By 2026

The Global Hereditary Angioedema Market was valued at US$ 1,563.7 million in 2016 and is expected to witness a robust CAGR of 9.1% over the forecast period (2017 – 2025).
Hereditary Angioedema Market To Grow Like
Never Before By 2026
Over-the-counter Drugs Market, by Product Type (Analgesics and Pain
Relievers, Cough, Cold and Flu Products, Dermatological Products, Vitamin &
Mineral Supplements, Gastrointestinal Products, Sleeping Aids, Smoking
Cessation Aids, Ophthalmic Products, and Others), by Route of Administration
(Oral, Topical, and Others), by Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies, and Others), and by Geography (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global
Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
The Global Hereditary Angioedema Market was valued at US$ 1,563.7 million in 2016 and is
expected to witness a robust CAGR of 9.1% over the forecast period (2017 – 2025).
Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an
autosomal dominant mutation of the genes. The current treatments of the condition include the HAE
drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes
swelling particularly of the face and airways and abdominal cramping. The World Allergy Organization
(WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein
inhibitors and other drugs approved to treat hereditary angioedema.
Market Dynamics
The major factor driving growth of the hereditary angioedema market include intense R&D initiatives
by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the
presence of promising drug pipeline. For instance, in 2017, Attune Pharmaceuticals, revealed the
successful study results the first preclinical data results for ATN-249, a novel orally administered
plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). Also, the approval of
novel therapies by the regulatory agencies is expected to be a factor augmenting market growth. For
instance, in 2014, the FDA approved Ruconest manufactured by Pharming Healthcare, a recombinant
C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE.
However, lack of awareness regarding the diseases, inefficient diagnosis and high cost of drugs are the
Detailed Segmentation:
•Global Hereditary Angioedema Market, By Drug Class:
•C1 Esterase Inhibitor
•Kallikrein Inhibitor
•Bradykinin Receptor
•Attenuated Androgens
•Global Hereditary Angioedema Market, By Route of Administration:
•Global Hereditary Angioedema Market, By Distribution Channel:
•Hospital Pharmacies
•Retail Pharmacies
Increasing prevalence and rising awareness of hereditary angioedema to augment market growth
The increasing number of hereditary angioedema cases and the hereditary nature giving the disease an
ability to pass the defective gene to the future generations is expected to propel market growth.
According to the survey by International Hereditary Angioedema Organization (HAEi), 2015, the
global prevalence of hereditary angioedema is estimated to be around 1 in 10,000 to 50,000 people,
meaning that around a quarter million people suffer globally from this rare and life threatening
deficiency condition.
Also, according to National Association for Rare Disorders, 2016, the risk of passing the abnormal
gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting
child. North America dominates the hereditary angioedema market, owing to the higher number of
drugs approved in the regions, presence of major manufacturers and the presence of various
organizations serving HAE patients. In 2017, the U.S. Food and Drug Administration (FDA) approved
Haegarda (C1-esterase inhibitor) manufactured by CSL Behring for routine prophylaxis to prevent
HAE attacks in adolescent and adult patients.
Ask For Sample Copy Of This Report :
Increasing support from non-profit organizations towards intensive research is expected to
accelerate the market
The organizations are focusing on increasing global HAE awareness by educating and empowering
patient, providing access to suitable therapy/treatment. The organizations are also working towards
intensive research to find a cure. For instance, the non-profit organization named HAEi is dedicated
towards spreading awareness of C1-inhibitor deficiencies and to improve diagnosis, facilitating access
to reimbursement of the HAE therapies, enabling lifelong health for the global patients.
The organization also initiated the Global Access Program (HAEi GAP) in 2015, to provide the access
to the approved HAE medications in countries where modern therapies are otherwise unavailable.
Moreover, the non-profit organization- US Hereditary Angioedema Association is committed to
advance and conduct clinical research designed to improve the lives of HAE patients. The major
players operating the global hereditary angioedema market include CSL Behring, Shire Plc., Pharming
Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead
Pharmaceuticals, Adverum Biotechnologies and Attune Pharmaceuticals, Inc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
ravikiran257   documents Email
Health and Medicine
File Size
381 KB
hereditary, Hereditary Angioedema
Report inappropriate content